| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6960577 | CHEPLAPHARM | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) | |
Zyprexa is owned by Cheplapharm.
Zyprexa contains Olanzapine.
Zyprexa has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Zyprexa are:
- US6960577
Zyprexa was authorised for market use on 30 September, 1996.
Zyprexa is available in tablet;oral dosage forms.
Zyprexa can be used as prozac and olanzapine in combination for the acute treatment of treatment resistant depression in adults.
The generics of Zyprexa are possible to be released after 01 November, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-591) | Mar 19, 2012 |
| New Patient Population(NPP) | Dec 04, 2012 |
| Pediatric Exclusivity(PED) | Jun 04, 2013 |
Drugs and Companies using OLANZAPINE ingredient
Market Authorisation Date: 30 September, 1996
Treatment: Prozac and olanzapine in combination for the acute treatment of treatment resistant depression in adults
Dosage: TABLET;ORAL
How can I launch a generic of ZYPREXA before it's drug patent expiration?
More Information on Dosage
ZYPREXA family patents
